• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Intracortical Visual Prosthesis achieves 2 years of successful testing

News
Article

The system is comprised of 25 miniaturized wireless stimulators with 400 electrodes that are implanted permanently.

Image Credit: AdobeStock/Mopic)

Image Credit: AdobeStock/Mopic)

The Intracortical Visual Prosthesis (ICVP), a wireless visual prosthesis brain implant, has achieved 2 years of successful testing after surgical implantation in a patient who is blind. The prosthesis bypasses the optic nerve and sends images directly to the patient's brain to create artificial sight, reported Phillip Troyk, PhD, who led the multi-institution team that developed the technology. He is the executive director of the Pritzker Institute of Biomedical Science and Engineering and professor of biomedical engineering, Illinois Institute of Technology, Chicago.

The system is comprised of 25 miniaturized wireless stimulators with 400 electrodes that are implanted permanently. The clinical testing of the prosthesis “provides study participants with an improved ability to navigate and perform basic, visually guided tasks,” according to a recent press release.

The ICVP works by focusing on creating artificial vision by bypassing damaged optical pathways to directly stimulate the visual cortex.

The patient implanted with the ICVP lost his vision because of a series of detached retinal surgeries and infection.

When using the ICVP, an external stimulator is strapped to the patient’s head to activate the implanted electrodes. He wears glasses with an attached camera that transmits his surroundings to his brain. The information viewed by the patient differs from normal vision, in that it is a series of electrical phosphenes that are produced by the stimulation of the neurons in the visual cortex. The phosphenes advise the patient that something is in his vicinity.

In commenting on the technologic progress, Troyk said, “The past 2 years have been nothing short of extraordinary. Witnessing the ICVP bring about a new form of visual perception to individuals with blindness has reinforced our commitment to this endeavor. Our focus remains steadfast on improving and understanding how this technology can further aid in navigation and performing daily visual tasks for those without biological vision.”

Research volunteers are being sought to participate in the project; they must have lost vision as adults who previously had normal or near-normal vision for at least the first 10 years. Following the implantation and about 1 month of recovery, participants will be followed for 1 to 3 years, depending on the date of implantation.

The Illinois Institute of Technology is collaborating on this project with Rush University Medical Center, The Chicago Lighthouse, both in Chicago; the Wilmer Eye Institute at Johns Hopkins, Baltimore; the University of Texas at Dallas; Microprobes for Life Science, Gaithersburg, MD; Sigenics Inc., Chicago; and the University of Chicago, Dr. Troyk is the principal investigator. The National Institutes of Health is funding the project.

Related Videos
Video 6 - "Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases"
Video 5 - "Evolving Role of Steroids and Laser In DME"
Video 4 - "A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy"
Video 3 - "Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent"
Video 2 - "A Case of Neovascular AMD with Persistent Subretinal Fluid"
Video 1 - "A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment"
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
© 2024 MJH Life Sciences

All rights reserved.